Research demonstrates cross-resistance patterns in Neisseria gonorrhoeae, suggesting implications for topoisomerase inhibitor surveillance.
Genetic background modulated the phenotypic effects of a zoliflodacin-resistance determinant on fitness and cross-resistance to gepotidacin. These findings inform strategies for introducing the new topoisomerase inhibitors into clinical use and for surveillance of resistance.
No takes yet. Share an insight, caveat, or question.
Mukherjee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: